email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
91 - 105
of 3612 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
Next
Sirius Starts Phase I Trial in Australia of siRNA Aimed at Thromboembolic Disorders
$5.00
Available
Inmagene Exercises Option for Two HutchMed Candidates in $460 Million Deal
$5.00
Available
Biosyngen Nabs US Fast Track Status for TIL Cell Therapy in Liver Cancer
$5.00
Available
Sanofi Invests in Graviton and its Lead Product, a ROCK2 Inhibitor in-licensed from Beijing Tide
$5.00
Available
Biosion Cleared to Start US Trials of Novel anti-SIRPα mAb for Solid Tumor Cancers
$5.00
Available
DualityBio and BioNTech announce US Fast Track Status for ADC in Ovarian Cancer
$5.00
Available
US Legislators Target WuXi Bio and BGI; Aim to Prevent Transfer of US Genomic Data
$5.00
Available
Data from Qilu Pharma’s Approved ALK Inhibitor for NSCLC Published in Journal
$5.00
Available
Gracell Approved for US Trial of FasTCAR in Early Multiple Myeloma
$5.00
Available
Vesicure Announces Positive Early Results of Exosome Technology for siRNA Delivery
$5.00
Available
ArriVent Completes $175 Million NASDAQ IPO to Bring Assets from China to the US
$5.00
Available
Jiuzhou Pharma Earmarks $42 Million for New CDMO Site in Japan
$5.00
Available
Refreshgene’s siRNA Therapy Enables Children with Genetic Deafness to Hear
$5.00
Available
Alphamab and 3D Medicines Out-License PD-L1 to India’s Glenmark
$5.00
Available
Biocytogen Launches New Division to Partner Antibodies and License Mice Platforms
$5.00
Available